drugset / Trial / NCT06678074
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Phase 1/2
Active not recruiting
10 enrolled
Implicit Bioscience
University of Virginia · collabWashington University School of Medicine · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).
Timeline
- Start
- 2025-02-06
- Primary completion
- 2026-06-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IC14 | Monoclonal antibody | 20 mg/kg | Intravenous |